Want to join the conversation?
$RCL, which competes with $NCLH and $CCL, said the company exceeded guidance for 2Q16 by $0.09 a share and the business is set to do better for the year than expected. $RCL added it works with three times as many tour operator partners as it did three years ago and has quadrupled the number of independent agencies it works with from 200 to 800.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.